RTI Biologics gets rights to Athersys' stem cell IP
Cell therapy company Athersys Inc. has licensed RTI Biologics Inc. (biological implants) rights to use its Multipotent Adult Progenitor Cell (MAPC) technologies to develop orthopedic implants.
- Medical Devices
- Implantable Devices
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.